Skip to main content
SpringerLink
Log in

Metastatic Pancreatic Cancer: Systemic Therapy

  • Chapter
  • First Online:
Book cover New Concepts in Diagnosis and Therapy of Pancreatic Adenocarcinoma

Part of the book series: Medical Radiology ((Med Radiol Diagn Imaging))

  • 894 Accesses

Abstract

Infiltrating ductal adenocarcinoma of the pancreas has an aggressive nature. Approximately 90% of patients have surgically unresectable disease at the time of diagnosis. In addition, the majority of the selected patients who undergo potentially curative resection for small, localised lesions inevitably develop recurrent or metastatic disease. Most systemic therapies have limited efficacy in patients with metastatic disease. Gemcitabine, with or without erlotinib, has modest clinical benefit and a marginal survival advantage in patients with metastatic pancreatic cancer and has become a standard of care for these patients. However, the median survival of patients with metastatic pancreatic cancer remains poor and is less than 6 months. This chapter gives an overview of the various monotherapy and combination chemotherapy regimens that have been evaluated in this disease, discusses the studies which have incorporated molecularly targeted agents into the treatment regimens, and highlights the challenges in developing therapeutic strategies to improve survival in metastatic pancreatic cancer.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 89.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 119.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 169.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  • Alberts SR, Townley PM, Goldberg RM et al (2002) Gemcitabine and oxaliplatin for patients with advanced or metastatic pancreatic cancer: a North Central Cancer Treatment Group Phase I study. Ann Oncol 13:553–557

    Article  PubMed  CAS  Google Scholar 

  • Alberts SR, Townley PM, Goldberg RM et al (2003) Gemcitabine and oxaliplatin for metastatic pancreatic adenocarcinoma: a North Central Cancer Treatment Group phase II study. Ann Oncol 14:580–585

    Article  PubMed  CAS  Google Scholar 

  • Almoguerra C, Shibata D, Forrester K et al (1998) Most human carcinomas of the exocrine pancreas contain mutant c-K-ras genes. Cell 53:549–554

    Article  Google Scholar 

  • Baker CH, Solorzano CC, Fidler IJ (2002) Blockade of vascular endothelial growth factor receptor and epidermal growth factor receptor signaling for therapy of metastatic human pancreatic cancer. Cancer Res 62:1996–2003

    PubMed  CAS  Google Scholar 

  • Barone C, Cassano A, Corsi DC et al (2003) Weekly gemcitabine and 24-hour infusional 5-fluorouracil in advanced pancreatic cancer: a phase I–II study. Oncology 64:139–145

    Article  PubMed  CAS  Google Scholar 

  • Berlin JD, Catalano P, Thomas JP et al (2002) Phase III study of gemcitabine in combination with fluorouracil versus gemcitabine alone in patients with advanced pancreatic carcinoma: Eastern Cooperative Oncology Group Trial E2297. J Clin Oncol 20:3270–3275

    Article  PubMed  CAS  Google Scholar 

  • Bernard S, Noble S, Wilcosky T et al (1986) A phase II study of ifosfamide (IFOS) plus N-acetyl cysteine (NAC) in metastatic measurable pancreatic adenocarcinoma (abstract). Proc Am Soc Clin Oncol 5:328

    Google Scholar 

  • Bockhorn M, Hsuzuki Y, Xu L et al (2003) Differential vascular and transcriptional responses to anti-vascular endothelial growth factor antibody in orthotopic human pancreatic cancer xenografts. Clin Cancer Res 9:4221–4226

    PubMed  CAS  Google Scholar 

  • Bruns CJ, Solorzano CC, Harbison MT et al (2000) Blockade of the epidermal growth factor receptor signalling by a novel tyrosine kinase inhibitor leads to apoptosis of endothelial cells and therapy of human pancreatic carcinoma. Cancer Res 60:2926–2935

    PubMed  CAS  Google Scholar 

  • Bruns CJ, Shrader M, Harbison MT et al (2002) Effect of the vascular endothelial growth factor receptor-2 antibody DC-101 plus gemcitabine on growth, metastasis, and angiogenesis of human pancreatic cancer growing orthotopically in nude mice. Int J Cancer 102:101–108

    Article  PubMed  CAS  Google Scholar 

  • Buroker T, Kim PN, Groppe C et al (1979) 5-FU infusion with mitomycin C versus 5-FU infusion with methyl CCNU in the treatment of advanced upper gastrointestinal cancer. Cancer 44:1215–1221

    Article  PubMed  CAS  Google Scholar 

  • Burris HA, Moore MJ, Andersen J et al (1997) Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomised trial. J Clin Oncol 15:2403–2413

    PubMed  CAS  Google Scholar 

  • Carter SK (1975) The integration of chemotherapy into a combined modality approach for cancer treatment: VI. Pancreatic adenocarcinoma. Cancer Treat Rev 3:193–214

    Article  Google Scholar 

  • Cartwright TH, Cohn A, Varkey JA et al (2002) Phase II study of oral capecitabine in patients with advanced or metastatic pancreatic cancer. J Clin Oncol 20:160–164

    Article  PubMed  CAS  Google Scholar 

  • Cascinu S, Labianca R, Catalano V et al (2003) Weekly gemcitabine and cisplatin chemotherapy: a well-tolerated but ineffective chemotherapeutic regimen in advanced pancreatic cancer patients. A report from the Italian Group for the Study of Digestive Tract Cancer (GESCAD). Ann Oncol 14:205–208

    Article  PubMed  CAS  Google Scholar 

  • Casper ES, Green MR, Kelsen DP et al (1994) Phase II trial of gemcitabine (2′2-difluorodeoxycytidine) in patients with adenocarcinoma of the pancreas. Invest New Drugs 12:29–34

    Article  PubMed  CAS  Google Scholar 

  • Colucci G, Guiliani F, Gebbia V et al (2002) Gemcitabine alone or with cisplatin for the treatment of patients with locally advanced and/or metastatic pancreatic carcinoma: a prospective, randomised phase III study of the Gruppo Oncoliga del’Italia Meridionale. Cancer 94:902–910

    Article  PubMed  CAS  Google Scholar 

  • Correale P, Messinese S, Marsili S et al (2003) A novel bi weekly pancreatic cancer treatment schedule with gemcitabine, 5-fluorouracil and folinic acid. Br J Cancer 89:239–242

    Article  PubMed Central  PubMed  CAS  Google Scholar 

  • Corrie P, Mayer A, Shaw J et al (2002) Phase II study to evaluate combining gemcitabine with flutamide in advanced pancreatic cancer patients. Br J Cancer 87:716–719

    Article  PubMed Central  PubMed  CAS  Google Scholar 

  • Cubilla AL, Fitzgerald PJ (1975) Morphological patterns of primary nonendocrine human pancreas carcinoma. Cancer Res 35:2234–2248

    PubMed  CAS  Google Scholar 

  • Cubilla AL, Fitzgerald PJ (1976) Morphological lesions associated with human primary invasive nonendocrine pancreas cancer. Cancer Res 36:2690–2698

    PubMed  CAS  Google Scholar 

  • Cunningham D, Chau I, Stocken D et al (2005). Phase III randomised comaprison of gemcitabine versus gemcitabine plus capecitabine in patients with advanced pancreatic cancer. Eur J Cancer Suppl 3:4(abstract 4)

    Google Scholar 

  • El-Rayes BF, Zalupski MM, Shields AF et al (2003) Phase II study of gemcitabine, cisplatin and infusional fluorouracil in advanced pancreatic cancer. J Clin Oncol 21:2920–2925

    Article  PubMed  CAS  Google Scholar 

  • Evans TRJ, Lofts FJ, Mansi JL et al (1996) A phase II study of continuous-infusion 5-fluorouracil with cisplatin and epirubicin in inoperable pancreatic cancer. Br J Cancer 73:1260–1264

    Article  PubMed Central  PubMed  CAS  Google Scholar 

  • Feliu J, Mel R, Borrega P et al (2003) Phase II study of a fixed dose-rate infusion of gemcitabine associated with uracil/tegafur in advanced carcinoma of the pancreas. Ann Oncol 13:1756–1762

    Article  Google Scholar 

  • Fjallskog MLH, Lejonklou MH, Oberg KE et al (2003) Expression of molecular targets for tyrosine kinase receptor antagonists in malignant endocrine pancreatic tumors. Clin Cancer Res 9:1469–1473

    PubMed  Google Scholar 

  • Ghandi V, Plunkett W (1990) Modulatory activity of 2′2′-difluorodeoxycytidine on the phosphorylation and cytotoxicity of arabinosyl nucleosides. Cancer Res 50:3675–3680

    Google Scholar 

  • Grindey GB, Hertel LW, Plunkett W (1990) Cytotoxicity and anti-tumour activity of 2′2′-difluorodeoxycytidine (Gemcitabine). Cancer Invest 8:313–318

    Article  PubMed  CAS  Google Scholar 

  • Hausen R, Quebbman E, Ritch P et al (1988) Continous 5-fluorouracil infusion in carcinoma of the pancreas. Am J Med Sci 295:91–93

    Article  Google Scholar 

  • Heinemann V, Hertel L, Grindey GB (1988) Comparison of the cellular pharmacokinetics and toxicity of 2′2′-difluorodeoxycytidine and 1-b-D-arabinofuranasyl cytosine. Cancer Res 48:4024–4031

    PubMed  CAS  Google Scholar 

  • Herrmann R, Bodoky G, Ruhstaller T et al (2007) Gemcitabine plus capecitabine compared with gemcitabine alone in advanced pancreatic cancer: A randomized, multicenter, phase III trial of the Swiss Group for Clinical Cancer Research and the Central European Cooperative Oncology Group. J Clin Oncol 25:2212–2217

    Article  PubMed  CAS  Google Scholar 

  • Hertel W, Boder GB, Kroin JS et al (1990) Evaluation of the anti-tumour activity of gemcitabine (2′2′-difluorodeoxycytidine). Cancer Res 50:4417–4422

    PubMed  CAS  Google Scholar 

  • Hess V, Salzberg M, Borner M et al (2003) Combining capecitabine and gemcitabine in patients with advanced pancreatic carcinoma: a phase I/II trial. J Clin Oncol 21:66–68

    Article  PubMed  CAS  Google Scholar 

  • Hingorani SR, Petricoin EF, Maitra A et al (2003) Preinvasive and invasive ductal pancreatic cancer and its early detection in the mouse. Cancer Cell 4:437–449

    Article  PubMed  CAS  Google Scholar 

  • Hingorani SR, Wang L, Multani AS et al (2005) Trp53R172H and KrasG12D cooperate to promote chromosomal instability and widely metastatic pancreatic ductal adenocarcinoma in mice. Cancer Cell 7:469–483

    Article  PubMed  CAS  Google Scholar 

  • Hruban RH, Goggins M, Parsons J et al (2000a) Progression model for pancreatic cancer. Clin Cancer Res 6:2969–2972

    PubMed  CAS  Google Scholar 

  • Hruban RH, Wilentz RE, Kern SE (2000b) Genetic progression in the pancreatic ducts. Am J Pathol 156:1821–1825

    Article  PubMed Central  PubMed  CAS  Google Scholar 

  • Huang P, Chubb S, Hertel W et al (1991) Action of 2′2′-difluorodeoxycytidine on DNA synthesis. Cancer Res 51:6110–6117

    PubMed  CAS  Google Scholar 

  • Ianniello GP, Orditura M, Rossi A et al (2001) Gemcitabine plus epirubicin in advanced pancreatic cancer: a phase II multicenter trial. Oncol Rep 8:1111–1115

    PubMed  CAS  Google Scholar 

  • Itakura J, Ishiwata T, Shen B et al (2000) Concomitant over-expression of vascular endothelial growth factor and its receptors in pancreatic cancer. Int J Cancer 85:27–34

    Article  PubMed  CAS  Google Scholar 

  • Kanat O, Eurensel T, Kurt E et al (2004) Treatment of metastatic pancreatic cancer with a combination of gemcitabine and 5-fluorouracil: a single center phase II study. Tumori 90:192–195

    PubMed  CAS  Google Scholar 

  • Kern S, Hruban R, Hollingsworth MA et al (2001) A white paper: the product of a pancreas cancer think tank. Cancer Res 61:4923–4932

    PubMed  CAS  Google Scholar 

  • Kim TW, Kang HJ, Ahn JH et al (2002) Phase II study of gemcitabine, UFT and leucovorin in patients with advanced pancreatic cancer. Acta Oncol 41:689–694

    Article  PubMed  CAS  Google Scholar 

  • Kindler HL, Friberg G, Singh DA et al (2005) Phase II trial of bevacizumab plus gemcitabine in patients with advanced pancreatic cancer. J Clin Oncol 23:8033–8040

    Article  PubMed  CAS  Google Scholar 

  • Kindler HL, Niedzwiecki D, Hollis D et al (2007) A double-blind, placebo-controlled, randomized phase III trial of gemcitabine (G) plus bevacizumab (B) versus gemcitabine plus placebo (P) in patients (pts) with advanced pancreatic cancer (PC): a preliminary analysis of Cancer and Leukemia Group B (CALGB). J Clin Oncol 25:18s(abstact 4508)

    Google Scholar 

  • Klimstra DS, Longnecker DS (1994) K-ras mutations in pancreatic ductal proliferative lesions. Am J Pathol 145:1547–1550

    PubMed Central  PubMed  CAS  Google Scholar 

  • Kovach JS, Moertel CG, Schuft AJ et al (1974) A controlled study of combined 1, 3-bio(2-chlorethyl)-1-nitrosurea and 5-fluorouracil therapy for advanced gastric and pancreatic cancer. Cancer 33:563–567

    Article  PubMed  CAS  Google Scholar 

  • Kozuch P, Grossbard ML, Barzdins A et al (2001) Irinotecan combined with gemcitabine, 5-fluorouracil, leucovorin, and cisplatin (G-FLIP) is an effective and non cross-resistant treatment for chemotherapy refractory metastatic pancreatic cancer. Oncologist 6:488–495

    Article  PubMed  CAS  Google Scholar 

  • Kralidis E, Aebi S, Friess H et al (2003) Activity of raltitrexed and gemcitabine in advanced pancreatic cancer. Ann Oncol 14:574–579

    Article  PubMed  CAS  Google Scholar 

  • Lee J, Park JO, Kim WS et al (2004) Phase II study of gemcitabine combination with uracil – tegafur in metastatic pancreatic cancer. Oncology 66:32–37

    Article  PubMed  CAS  Google Scholar 

  • Li D, Xie K, Wolff R et al (2004) Pancreatic cancer. Lancet 363:1049–1057

    Article  PubMed  CAS  Google Scholar 

  • Louvet C, Andre T, Hammel P et al (2001) Phase II trial of bimonthly leucovorin, 5-fluorouracil and gemcitabine for advanced pancreatic adenocarcinoma (FOLFUGEM). Ann Oncol 12:675–679

    Article  PubMed  CAS  Google Scholar 

  • Louvet C, Andre T, Lledo G et al (2002) Gemcitabine combined with oxaliplatin in advanced pancreatic adenocarcinoma: final results of a GERCOR multicenter phase II study. J Clin Oncol 20:1512–1518

    Article  PubMed  CAS  Google Scholar 

  • Louvet C, Labianca R, Hammel P et al (2005) Gemcitabine in combination with oxaliplatin compared with gemcitabine alone in locally advanced or metastatic pancreatic cancer: results of a GERCOR and GISCARD phase III trial. J Clin Oncol 23:3509–3516

    Article  PubMed  CAS  Google Scholar 

  • Luo J, Guo P, Matsuda K et al (2001) Pancreatic cancer cell-derived vascular endothelial growth factor is biologically active in vitro and enhances tumorigenicity in vivo. Int J Cancer 92:361–369

    Article  PubMed  CAS  Google Scholar 

  • Mallinson GN, Rake MO, Cocking JB et al (1980) Chemotherapy in pancreatic cancer: results of a controlled, prospective, randomised, multicentre trial. Br Med J 281:1589–1591

    Article  PubMed Central  PubMed  CAS  Google Scholar 

  • Marantz A, Jovtis S, Almira E et al (2001) Phase II study of gemcitabine, 5-fluorouracil, and leucovorin in patients with pancreatic cancer. Semin Oncol 28:44–49

    Article  PubMed  CAS  Google Scholar 

  • Moertel CG (1976) Chemotherapy for gastrointestinal cancer. Clin Gastroenterol 5:777–793

    PubMed  CAS  Google Scholar 

  • Moore MJ, Goldstein D, Hamm J et al (2007) Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol 25:1960–1966

    Article  PubMed  CAS  Google Scholar 

  • Murad AM, Guimaeres RC, Aragao BC et al (2003) Phase II trial of the use of gemcitabine and 5-fluorouracil in the treatment of advanced pancreatic and biliary tract cancer. Am J Clin Oncol 26:151–154

    Article  PubMed  CAS  Google Scholar 

  • Neoptolemos JP, Stocken DD, Freiss H et al (2004) A randomized trial of chemoradiotherapy and chemotherapy after resection of pancreatic cancer. N Engl J Med 350:1200–1210

    Article  PubMed  CAS  Google Scholar 

  • Neri B, Cini G, Doni L et al (2002) Weekly gemcitabine plus epirubicin as effective chemotherapy for advanced pancreatic cancer: a multicenter phase II study. Br J Cancer 87:497–501

    Article  PubMed Central  PubMed  CAS  Google Scholar 

  • Ng SSW, Tsao MS, Nicklee T et al (2002) Effects of the epidermal growth factor receptor inhibitor OSI-774, Tarceva, on downstream signalling pathways and apoptosis in human pancreatic adenocarcinoma. Mol Cancer Ther 1:777–783

    PubMed  CAS  Google Scholar 

  • Novarino A, Chiappino I, Bertelli GF et al (2004) Phase II study of cisplatin, gemcitabine and 5-fluorouracil in advanced pancreatic cancer. Ann Oncol 15:474–477

    Article  PubMed  CAS  Google Scholar 

  • Oettle H, Richards D, Ramanathan R et al (2005) A phase III trial of pemetrexed plus gemcitabine versus gemcitabine in patients with unresectable or metastatic pancreatic cancer. Ann Oncol 16:1639–1645

    Article  PubMed  CAS  Google Scholar 

  • Oster MW, Gray R, Panasci L et al (1986) Chemotherapy for advanced pancreatic cancer: A comparison of 5-fluorouracil, adriamycin and mitomycin C (FAM) with 5-fluorouracil, streptozotcin and mitomycin C (FSM). Cancer 57:29–33

    Article  PubMed  CAS  Google Scholar 

  • Palmer KR, Kerr M, Knowles G et al (1994) Chemotherapy prolongs survival in inoperable pancreatic carcinoma. Br J Surg 81:882–885

    Article  PubMed  CAS  Google Scholar 

  • Petty RD, Nicolson MC, Skaria S et al (2003) A phase II study of mitomycin-C, cisplatin and protracted infusional 5-fluorouracil in advanced pancreatic carcinoma: efficacy and low toxicity. Ann Oncol 14:1100–1105

    Article  PubMed  CAS  Google Scholar 

  • Philip PA, Zalupski MM, Vaitkevicius VK et al (2001) Phase II study of gemcitabine and cisplatin in the treatment of patients with advanced pancreatic carcinoma. Cancer 92:569–577

    Article  PubMed  CAS  Google Scholar 

  • Philip PA, Benedetti C, Fenoglio-Preiser M et al (2007) Phase III study of gemcitabine [G] plus cetuximab [C] versus gemcitabine in patients [pts] with locally advanced or metastatic pancreatic adenocarcinoma [PC]: SWOG S0205 study. J Clin Oncol 25:18s(absract 4509)

    Google Scholar 

  • Rachamalla R, Malamud S, Grossbard ML et al (2004) Phase I dose-finding study of biweekly irinotecan in combination with fixed doses of 5-fluorouracil/leucovorin, gemcitabine and cisplatin (G-FLIP) in patients with advanced pancreatic cancer or other solid tumors. Anticancer Drugs 15:211–217

    Article  PubMed  CAS  Google Scholar 

  • Reni M, Cordio S, Milandri C et al (2005) Gemcitabine versus cisplatin, epirubicin, fluorouracil, and gemcitabine in advanced pancreatic cancer: a randomised controlled multicentre phase III trial. Lancet Oncol 6:369–376

    Article  PubMed  CAS  Google Scholar 

  • Rocha Lima CM, Savarese D, Bruckner H et al (2002) Irinotecan plus gemcitabine induces both radiographic and CA19-9 tumor marker responses in patients with previously untreated advanced pancreatic cancer. J Clin Oncol 20:1182–1191

    Article  PubMed  Google Scholar 

  • Rocha Lima C, Green M, Rotche R et al (2004) Irinotecan plus gemcitabine results in no survival advantage compared with gemcitabine monotherapy in patients with locally advanced or metastatic pancreatic cancer despite increased tumor response rate. J Clin Oncol 18:3776–3783

    Article  Google Scholar 

  • Rothenberg ML, Moore MJ, Cripps MC et al (1996) A phase II trial of gemcitabine in patients with 5-FU-refractory pancreas cancer. Ann Oncol 7:347–535

    Article  PubMed  CAS  Google Scholar 

  • Ryan DP, Kulke MH, Fuchs CS et al (2002) A phase II study of gemcitabine and docetaxel in patients with metastatic pancreatic carcinoma. Cancer 94:97–103

    Article  PubMed  CAS  Google Scholar 

  • Sacks H, Berrier J, Reitman D et al (1987) Meta-analysis of randomised controlled trials. N Engl J Med 316:450–455

    Article  PubMed  CAS  Google Scholar 

  • Schneider BP, Ganjoo KN, Seitz OE et al (2003) Phase II study of gemcitabine plus docetaxel in advanced pancreatic cancer: a Hoosier Oncology Group study. Oncology 65:218–223

    Article  PubMed  CAS  Google Scholar 

  • Shepard LC, Levy DE, Berlin JD et al (2004) Phase II study of gemcitabine in combination with docetaxel in patients with advanced pancreatic carcinoma (E1298). A trial of the Eastern Cooperative Oncology Group. Oncology 66:303–309

    Article  PubMed  CAS  Google Scholar 

  • Shi Q, Le X, Peng Z et al (2001) Constitutive Sp1 activity is essential for differential constitutive expression of vascular endothelial growth factor in human pancreatic adenocarcinoma. Cancer Res 61:4143–4154

    PubMed  CAS  Google Scholar 

  • Solorzano CC, Baker CH, Bruns CJ et al (2001) Inhibition of growth and metastasis of human pancreatic cancer growing in nude mice by PTK787/K222584, an inhibitor of the vascular endothelial growth factor receptor tyrosine kinase. Cancer Biother Radiopharm 16:359–370

    Article  PubMed  CAS  Google Scholar 

  • Stathopoulos GP, Rigatos SK, Dimopoulos MA et al (2003) Treatment of pancreatic cancer with a combination of irinotecan (CPT-11) and gemcitabine: a multicenter phase II study by the Greek Cooperative Group for Pancreatic Cancer. Ann Oncol 14:388–394

    Article  PubMed  CAS  Google Scholar 

  • Stathopoulos GP, Syrigos K, Polyzos A et al (2004) Front-line treatment of inoperable or metastatic pancreatic cancer with gemcitabine and capecitabine: an intergroup, multicenter, phase II study. Ann Oncol 15:224–229

    Article  PubMed  CAS  Google Scholar 

  • Stocken DD, Buchler MW, Dervenis C et al (2005) Meta-analysis of randomized adjuvant therapy trials for pancreatic cancer. Br J Cancer 92:1372–1381

    Article  PubMed Central  PubMed  CAS  Google Scholar 

  • Sultana A, Tudor Smith C, Cunningham D et al (2007) Meta-Analyses of chemotherapy for locally advanced and metastatic pancreatic cancer. J Clin Oncol 25:2607–2615

    Article  PubMed  Google Scholar 

  • Therasse P, Arbuck SG, Eisenhauer EA et al (2000) New guidelines to evaluate the response to treatment in solid tumors: European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 92:205–216

    Article  PubMed  CAS  Google Scholar 

  • Tobita K, Kijima H, Dowaki S et al (2003) Epidermal growth factor receptor expression in human pancreatic cancer: significance for liver metastasis. Int J Mol Med 11:305–309

    PubMed  CAS  Google Scholar 

  • Tomao S, Romiti A, Massidda B et al (2002) A phase II study of gemcitabine and tamoxifen in advanced pancreatic cancer. Anticancer Res 22:2361–2364

    PubMed  CAS  Google Scholar 

  • Tsuzuki Y, Mouta Carreira C, Bockborn M et al (2001) Pancreas microenvironment promotes VEGF expression and tumor growth: novel window models for pancreatic tumor angiogenesis and microcirculation. Lab Invest 81:1439–1451

    Article  PubMed  CAS  Google Scholar 

  • Ueda S, Ogata S, Tsuda H et al (2004) The correlation between cytoplasmic overexpression of epidermal growth factor receptor and tumor aggressiveness: poor prognosis in patients with pancreatic ductal adenocarcinoma. Pancreas 29:E1–E8

    Article  PubMed  Google Scholar 

  • van Cutsem E, Vervenne WL, Bennouna J et al (2009) Phase III trial of bevacizumab in combination with gemcitabine and erlotinib in patients with metastatic pancreatic cancer. J Clin Oncol 27:2231–2237

    Article  PubMed  Google Scholar 

  • Vasey PA, Evans J (2002) Principles of chemotherapy and drug development. In: Price P, Sikora K (eds) Treatment of cancer. Arnold, London, pp 103–129

    Google Scholar 

  • von Marschall Z, Cramer T, Hocker M et al (2000) De novo expression of vascular endothelial growth factor in human pancreatic cancer: evidence for an autocrine mitogenic loop. Gastroenterology 119:1358–1372

    Article  Google Scholar 

  • Wils J, Bleiberg H, Blijham G et al (1985) Phase II study of epirubicin in advanced adenocarcinoma of the pancreas. Eur J Cancer Clin Oncol 21:191–194

    Article  PubMed  CAS  Google Scholar 

  • Wils J, Kok T, Wagener OJ et al (1993) Activity of cisplatin in adenocarcinoma of the pancreas. Eur J Cancer 29:203–204

    Article  Google Scholar 

  • Yeo CJ, Cameron JL, Lillemoe KD et al (2002) Pancreaticoduodenectomy with or without distal gastrectomy and extended retroperitoneal lymphadenectomy for peri-ampullary adenocarcinoma, part 2: Randomised controlled trial evaluating survival, morbidity, and mortality. Ann Surg 236:355–366

    Article  PubMed Central  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Beatson West of Scotland Cancer Centre, 1053 Great Western Road, Glasgow, G12 OYN, UK

    Jennifer Brown & T. R. Jeffry Evans

  2. Beatson Laboratories, University of Glasgow, Garscube Estate, Switchback Road, Glasgow, G61 1BD, UK

    T. R. Jeffry Evans

Authors
  1. Jennifer Brown
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. T. R. Jeffry Evans
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to T. R. Jeffry Evans .

Editor information

Editors and Affiliations

  1. , Radiological, Oncological, and Pathologi, Sapienza , Università di Roma, Polo Pontino, Latina, Italy

    Andrea Laghi

Rights and permissions

Reprints and permissions

Copyright information

© 2010 Springer-Verlag Berlin Heidelberg

About this chapter

Cite this chapter

Brown, J., Evans, T.R.J. (2010). Metastatic Pancreatic Cancer: Systemic Therapy. In: Laghi, A. (eds) New Concepts in Diagnosis and Therapy of Pancreatic Adenocarcinoma. Medical Radiology(). Springer, Berlin, Heidelberg. https://doi.org/10.1007/174_2010_3

Download citation

  • DOI: https://doi.org/10.1007/174_2010_3

  • Published:

  • Publisher Name: Springer, Berlin, Heidelberg

  • Print ISBN: 978-3-540-85380-0

  • Online ISBN: 978-3-540-85381-7

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation